CN101255170A - 2,3－二氢－6－硝基咪唑并[2,1－b]唑化合物 - Google Patents

2,3－二氢－6－硝基咪唑并[2,1－b]唑化合物 Download PDF

Info

Publication number
CN101255170A
CN101255170A CNA2007100040371A CN200710004037A CN101255170A CN 101255170 A CN101255170 A CN 101255170A CN A2007100040371 A CNA2007100040371 A CN A2007100040371A CN 200710004037 A CN200710004037 A CN 200710004037A CN 101255170 A CN101255170 A CN 101255170A
Authority
CN
China
Prior art keywords
group
halogen
alkyl
unsubstituted
replacement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007100040371A
Other languages
English (en)
Chinese (zh)
Inventor
壶内英继
佐佐木博文
黑田英明
糸谷元宏
长谷川武司
原口佳和
黑田武志
松崎敬之
田井国宪
小松真
松本真
桥诘博之
富重辰夫
清家祐治
川崎昌则
住田卓美
宫村伸
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of CN101255170A publication Critical patent/CN101255170A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CNA2007100040371A 2002-10-11 2003-10-10 2,3－二氢－6－硝基咪唑并[2,1－b]唑化合物 Pending CN101255170A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002298259 2002-10-11
JP2002298259 2002-10-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB2003801017508A Division CN100366624C (zh) 2002-10-11 2003-10-10 2,3-二氢-6-硝基咪唑并[2,1-b]唑化合物

Publications (1)

Publication Number Publication Date
CN101255170A true CN101255170A (zh) 2008-09-03

Family

ID=32089299

Family Applications (4)

Application Number Title Priority Date Filing Date
CNA2007100040371A Pending CN101255170A (zh) 2002-10-11 2003-10-10 2,3－二氢－6－硝基咪唑并[2,1－b]唑化合物
CN201110416170.4A Expired - Lifetime CN102532162B (zh) 2002-10-11 2003-10-10 2,3-二氢-6-硝基咪唑并[2,1-b]噁唑化合物
CNB2003801017508A Expired - Lifetime CN100366624C (zh) 2002-10-11 2003-10-10 2,3-二氢-6-硝基咪唑并[2,1-b]唑化合物
CNA2007100040367A Pending CN101172981A (zh) 2002-10-11 2003-10-10 2,3－二氢－6－硝基咪唑并[2,1－b]唑化合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201110416170.4A Expired - Lifetime CN102532162B (zh) 2002-10-11 2003-10-10 2,3-二氢-6-硝基咪唑并[2,1-b]噁唑化合物
CNB2003801017508A Expired - Lifetime CN100366624C (zh) 2002-10-11 2003-10-10 2,3-二氢-6-硝基咪唑并[2,1-b]唑化合物
CNA2007100040367A Pending CN101172981A (zh) 2002-10-11 2003-10-10 2,3－二氢－6－硝基咪唑并[2,1－b]唑化合物

Country Status (26)

Country Link
US (1) US7262212B2 (enExample)
EP (2) EP2570418A3 (enExample)
JP (1) JP4186065B2 (enExample)
KR (1) KR100723847B1 (enExample)
CN (4) CN101255170A (enExample)
AR (4) AR041198A1 (enExample)
AU (1) AU2003272979B2 (enExample)
BE (1) BE2014C053I2 (enExample)
BR (1) BRPI0314344B8 (enExample)
CA (1) CA2497569C (enExample)
CY (2) CY1113578T1 (enExample)
DK (1) DK1555267T3 (enExample)
ES (1) ES2400179T3 (enExample)
FR (1) FR14C0066I2 (enExample)
HU (1) HUS1400046I1 (enExample)
LU (1) LU92517I2 (enExample)
MX (1) MXPA05003674A (enExample)
MY (1) MY139244A (enExample)
PL (3) PL404913A1 (enExample)
PT (1) PT1555267E (enExample)
RU (1) RU2326121C3 (enExample)
SI (1) SI1555267T1 (enExample)
TW (1) TWI347946B (enExample)
UA (1) UA83200C2 (enExample)
WO (1) WO2004033463A1 (enExample)
ZA (1) ZA200501033B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110615800A (zh) * 2019-10-16 2019-12-27 李丽丽 硝基咪唑类化合物及其制备方法和用途

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60144284D1 (de) 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
BR0313566A (pt) 2002-10-15 2005-06-21 Otsuka Pharma Co Ltd Composto de 4-nitroimidazol 1-substituìdo, método para preparar um composto de 4-nitroimidazol, método para preparar um composto de 4-nitroimidazol 1-substituìdo, derivado de 4-nitroimidazol, e, composto
JP4761756B2 (ja) * 2003-10-31 2011-08-31 大塚製薬株式会社 ２，３−ジヒドロイミダゾ［２，１−ｂ］オキサゾ−ル化合物
BRPI0414909A (pt) * 2003-10-31 2006-11-07 Otsuka Pharma Co Ltd composto, agente antituberculoso, e, método para produzir um composto
TWI300409B (en) 2004-02-18 2008-09-01 Otsuka Pharma Co Ltd Method for producing 4-nitroimidazole compound
CN1938292B (zh) 2004-03-31 2011-10-05 日本曹达株式会社 环胺化合物和有害生物防除剂
JP4789966B2 (ja) * 2004-04-09 2011-10-12 大塚製薬株式会社 医薬組成物
JP4787529B2 (ja) * 2004-04-09 2011-10-05 大塚製薬株式会社 医薬組成物
WO2007002057A1 (en) * 2005-06-20 2007-01-04 Schering Corporation Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists
AU2006273355B2 (en) * 2005-07-28 2012-01-19 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical composition comprising 2 , 3-dihydro-6-nitroimidazo [2 , 1-B] oxazole derivatives
JP5105818B2 (ja) * 2005-10-05 2012-12-26 大塚製薬株式会社 医薬組成物
TWI368509B (en) * 2005-10-05 2012-07-21 Otsuka Pharma Co Ltd Antituberculous therapeutic drugs and kit containing the same
EA014057B1 (ru) 2005-10-06 2010-08-30 Ниппон Сода Ко., Лтд. Поперечно связанные соединения циклических аминов и средства для борьбы с вредителями
TW200800268A (en) * 2005-11-04 2008-01-01 Otsuka Pharma Co Ltd Medicinal composition showing improved drug absorbability
AU2006333522A1 (en) 2005-12-21 2007-07-12 Decode Genetics, Ehf. Biaryl nitrogen heterocycle inhibitors of LTA4H for treating inflammation
AU2007216580B2 (en) * 2006-02-13 2012-09-27 Merck Serono Sa Sulfonamide derivatives for the treatment of bacterial infections
JP2007297305A (ja) * 2006-04-28 2007-11-15 Daiso Co Ltd Ｎ−（２，３−エポキシ−２−メチルプロピル）フタルイミドの製造法
WO2008106128A2 (en) * 2007-02-26 2008-09-04 Vitae Pharmaceuticals, Inc. CYCLIC UREA AND CARBAMATE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1
AR070301A1 (es) 2007-05-08 2010-03-31 Otsuka Pharma Co Ltd Compuesto epoxi y metodo para producir el mismo
EP2183229B1 (en) * 2007-07-26 2012-04-18 Vitae Pharmaceuticals, Inc. Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
AR067927A1 (es) * 2007-08-15 2009-10-28 Glaxo Group Ltd Quinolinas sustituidas, composiciones y combinaciones que las comprenden y el uso de las mismas en la preparacion de un medicamento para tratamiento de enfermedades inflamatorias y/o alergicas del tracto respiratorio.
WO2009050204A1 (en) * 2007-10-16 2009-04-23 Glaxo Group Limited Quinoline derivatives used to treat inflammatory and allergic diseases
AR069207A1 (es) * 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
CA2708303A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
TW200934490A (en) * 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
WO2009094169A1 (en) 2008-01-24 2009-07-30 Vitae Pharmaceuticals, Inc. Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2252598A2 (en) * 2008-02-11 2010-11-24 Vitae Pharmaceuticals, Inc. 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CA2715290A1 (en) * 2008-02-15 2009-08-20 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2274287B1 (en) * 2008-03-18 2016-03-09 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
EP2254892B1 (en) * 2008-03-26 2014-04-23 Global Alliance For Tb Drug Development Bicyclic nitroimidazoles covalently linked to substituted phenyl oxazolidinones
WO2009134392A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8592410B2 (en) 2008-05-01 2013-11-26 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1
WO2009134384A1 (en) * 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
ES2421537T3 (es) * 2008-05-01 2013-09-03 Vitae Pharmaceuticals Inc Inhibidores cíclicos de la 11beta-hidroxiesteroide deshidrogenasa 1
ES2432150T3 (es) 2008-07-25 2013-12-02 Boehringer Ingelheim International Gmbh Inhibidores cíclicos de la 11 beta-hidroxiesteroide deshidrogenasa 1
JP5777030B2 (ja) 2008-07-25 2015-09-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １１β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
EA201170349A1 (ru) * 2008-08-18 2011-08-30 Йейл Юниверсити Модуляторы mif
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
US8558005B2 (en) * 2008-08-21 2013-10-15 Dynamit Nobel Gmbh Explosivstoff-Und Systemtechnik Methods for the production of 2-halo-4-nitroimidazole and intermediates thereof
WO2010143007A1 (en) * 2009-06-10 2010-12-16 Dynamit Nobel Gmbh Explosivstoff-Und Systemtechnik Method for the production of 2-halogeno-4-nitroimidazole
CA2744946A1 (en) 2009-02-04 2010-08-12 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
TW201039034A (en) * 2009-04-27 2010-11-01 Chunghwa Picture Tubes Ltd Pixel structure and the method of forming the same
GEP20156309B (en) * 2009-04-30 2015-07-10 Vitae Pharmaceuticals Inc Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8680093B2 (en) 2009-04-30 2014-03-25 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8927539B2 (en) 2009-06-11 2015-01-06 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure
WO2011002910A1 (en) 2009-07-01 2011-01-06 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
AU2010278777B2 (en) * 2009-07-31 2015-05-07 Global Alliance For Tb Drug Development Nitroimidazooxazines and their uses in anti-tubercular therapy
US9198913B2 (en) 2009-07-31 2015-12-01 Global Alliance For Tb Drug Development Nitroimidazooxazines and their uses in anti-tubercular therapy
WO2011014776A1 (en) * 2009-07-31 2011-02-03 Global Alliance For Tb Drug Development Nitroimidazooxazine and nitroimidazooxazole analogues and their uses
WO2011052522A1 (ja) 2009-10-26 2011-05-05 富士フイルムＲｉファーマ株式会社 感染症診断薬
TW201200523A (en) 2010-01-29 2012-01-01 Otsuka Pharma Co Ltd Synthetic intermediate of oxazole compound and method for producing the same
GB201012209D0 (en) * 2010-05-31 2010-09-08 Ge Healthcare Ltd In vivo imaging agent
EP2582698B1 (en) 2010-06-16 2016-09-14 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
WO2011161128A1 (en) 2010-06-25 2011-12-29 Boehringer Ingelheim International Gmbh Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
EA201300522A1 (ru) 2010-11-02 2013-11-29 Бёрингер Ингельхайм Интернациональ Гмбх Фармацевтические комбинации для лечения метаболических нарушений
US9051333B2 (en) 2011-04-15 2015-06-09 Otsuka Pharmaceutical Co., Ltd. 6,7-dihydroimidazo [2,1-b] [1,3]oxazine bactericides
JP2015006994A (ja) * 2011-10-28 2015-01-15 大正製薬株式会社 ジヒドロイミダゾオキサゾール誘導体
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases
FR3000064A1 (fr) * 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes
WO2015049693A1 (en) 2013-10-04 2015-04-09 Council Of Scientific & Industrial Research 6-NITRO-2,3-DIHYDROIMIDAZO[2,1-b]OXAZOLES AND A PROCESS FOR THE PREPARATION THEREOF
CN103524492A (zh) * 2013-10-23 2014-01-22 中国药科大学 侧链含硝基咪唑基团取代的喹诺酮类化合物、其制备及用途
TWI687409B (zh) 2014-08-28 2020-03-11 日商大塚製藥股份有限公司 稠合雜環化合物
JP6467042B2 (ja) * 2014-10-21 2019-02-06 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ 抗マイコバクテリア剤としての置換１，２，３−トリアゾール−１−イル−メチル−２，３−ジヒドロ−２−メチル−６−ニトロイミダゾ［２，１−ｂ］オキサゾールとその調製方法
CN105732659B (zh) * 2014-12-12 2019-07-16 上海阳帆医药科技有限公司 硝基咪唑类化合物及其制备方法和在制药中的用途
BR112017015744A2 (pt) * 2015-01-29 2018-03-13 Medshine Discovery Inc composto apresentando uma estrutura de fórmula (i), um sal farmaceuticamente aceitável do mesmo ou um isômero ótico do mesmo, composição farmacêutica e uso do composto de fórmula (i) para o tratamento e prevenção de mycobacterium tuberculosis ou outras infecções microbianas
EP3275862B1 (en) 2015-03-27 2020-08-12 Otsuka Pharmaceutical Co., Ltd. Method for producing 1-(4-hydroxyphenyl)-4-(4-trifluoromethoxyphenoxy)piperidine or salt thereof
CN106317072B (zh) * 2015-06-17 2020-03-17 盟科医药技术(上海)有限公司 用于分枝杆菌感染治疗的杂环化合物及其应用
JP6905506B2 (ja) 2016-02-26 2021-07-21 大塚製薬株式会社 ピペリジン誘導体
CN105859628B (zh) * 2016-04-19 2018-08-07 清远职业技术学院 一种抗菌化合物对n咪唑苯甲醛缩邻甲苯胺希夫碱及其制备方法和应用
US20190276475A1 (en) * 2016-07-22 2019-09-12 Medshine Discovery Inc. Crystal and salt of nitroimidazole, and manufacturing method thereof
SMT202100727T1 (it) * 2017-08-16 2022-01-10 Glaxosmithkline Ip Dev Ltd Nuovi composti
CN112236141A (zh) 2018-06-11 2021-01-15 大塚制药株式会社 包含德拉马尼的组合物
CN109705022A (zh) * 2018-12-28 2019-05-03 上海彩迩文生化科技有限公司 一种芳香胺中间体的制备方法
CN112300192B (zh) * 2019-08-02 2023-08-11 南京长澳医药科技有限公司 硝基咪唑类化合物及其制备方法和用途
CN110483549B (zh) * 2019-08-30 2021-03-05 沈阳药科大学 一种硝基咪唑吡喃类抗结核药物的制备方法
CN112156088B (zh) * 2020-10-30 2021-08-31 健民药业集团股份有限公司 一种化合物在制备结核分枝杆菌抑制剂中的用途
CN113603706A (zh) * 2021-08-04 2021-11-05 深圳市泰力生物医药有限公司 德拉马尼的晶型、含有该晶型的活性药物和药物组合物
JPWO2024024938A1 (enExample) 2022-07-29 2024-02-01
CN115368252B (zh) * 2022-09-19 2024-01-12 西北农林科技大学 一种4-胺基酚类衍生物及应用
CN116640106B (zh) * 2023-05-11 2024-03-08 郑州大学 一种苯基哌嗪类化合物及其制备方法、应用
CN119059990B (zh) * 2024-11-01 2025-02-07 安徽昊帆生物有限公司 1-氨基甲酸叔丁酯哌嗪的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668127A (en) 1995-06-26 1997-09-16 Pathogenesis Corporation Nitroimidazole antibacterial compounds and methods of use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110615800A (zh) * 2019-10-16 2019-12-27 李丽丽 硝基咪唑类化合物及其制备方法和用途

Also Published As

Publication number Publication date
MXPA05003674A (es) 2005-06-08
US7262212B2 (en) 2007-08-28
LU92517I2 (fr) 2014-10-13
RU2005114017A (ru) 2006-01-20
AR091771A2 (es) 2015-02-25
AU2003272979A1 (en) 2004-05-04
MY139244A (en) 2009-09-30
HUS1400046I1 (hu) 2017-04-28
HK1085463A1 (zh) 2006-08-25
US20060094767A1 (en) 2006-05-04
RU2326121C2 (ru) 2008-06-10
CN102532162B (zh) 2015-05-27
PL409525A1 (pl) 2014-11-10
CN101172981A (zh) 2008-05-07
SI1555267T1 (sl) 2013-05-31
EP2570418A3 (en) 2013-07-03
CN1705670A (zh) 2005-12-07
CY1113578T1 (el) 2016-06-22
CY2014041I2 (el) 2016-07-27
CY2014041I1 (el) 2016-07-27
RU2326121C3 (ru) 2021-09-17
KR20050061473A (ko) 2005-06-22
TWI347946B (en) 2011-09-01
ES2400179T3 (es) 2013-04-08
DK1555267T3 (da) 2013-02-11
BRPI0314344B1 (pt) 2019-11-26
EP2570418A2 (en) 2013-03-20
BRPI0314344B8 (pt) 2021-05-25
JP4186065B2 (ja) 2008-11-26
PL217919B1 (pl) 2014-09-30
CA2497569A1 (en) 2004-04-22
AR041198A1 (es) 2005-05-04
CN102532162A (zh) 2012-07-04
AU2003272979B2 (en) 2009-07-23
PL376157A1 (en) 2005-12-27
PT1555267E (pt) 2013-01-29
FR14C0066I2 (fr) 2015-05-22
JP2004149527A (ja) 2004-05-27
EP1555267A4 (en) 2010-08-18
WO2004033463A1 (ja) 2004-04-22
CA2497569C (en) 2011-05-24
PL404913A1 (pl) 2013-09-30
KR100723847B1 (ko) 2007-05-31
ZA200501033B (en) 2006-06-28
CN100366624C (zh) 2008-02-06
BR0314344A (pt) 2005-07-12
UA83200C2 (en) 2008-06-25
BE2014C053I2 (enExample) 2022-08-30
HK1171018A1 (en) 2013-03-15
AR086485A2 (es) 2013-12-18
TW200420568A (en) 2004-10-16
FR14C0066I1 (enExample) 2014-10-17
EP1555267B1 (en) 2013-01-16
AR089950A2 (es) 2014-10-01
EP1555267A1 (en) 2005-07-20

Similar Documents

Publication Publication Date Title
CN100366624C (zh) 2,3-二氢-6-硝基咪唑并[2,1-b]唑化合物
CN104822687B (zh) 抗纤维化吡啶酮类
CN101029022B (zh) 含氮芳环衍生物的制备方法
JP4787529B2 (ja) 医薬組成物
CN113272301A (zh) 杂环类化合物、中间体、其制备方法及应用
CN110452216A (zh) 抗纤维化吡啶酮类
CN106164047B (zh) 作为阿立新受体拮抗剂的1,2-取代环戊烷
TW201036958A (en) Pyridazinone compounds
UA75880C2 (en) Indazole compounds as antiproliferative agents, a pharmaceutical composition (variants) and a method for treatment of diseases and disorders (variants) associated wiyh unwanted angiogenesis and/or cellular proliferation
WO2020103817A1 (zh) TGF-βR1抑制剂及其应用
CN107001271B (zh) 羟基脒类衍生物、其制备方法及其在医药上的应用
CN109415358A (zh) 作为RORγt调节剂的6-氨基吡啶-3-基噻唑
CN106459027B (zh) 作为TARP-γ8依赖性AMPA受体拮抗剂的6-取代-3H-1,3-苯并噻唑-2-酮化合物
CN111356695A (zh) 新的三环化合物
JP5345174B2 (ja) 医薬組成物
CN106604918B (zh) 多环hERG激活剂
HK1171018B (en) 2,3-dihydro-6-nitroimidazo (2, 1-b) oxazoles
HK1120499A (en) 2,3-dihydro-6-nitroimidazo [2,1-b] oxazoles
HK1118543A (en) 2,3-dihydro-6-nitroimidazo (2,1-b) oxazoles
HK1085463B (en) 2,3-dihydro-6-nitroimidazo (2,1-b) oxazoles
HK40048952A (en) Heterocyclic compound, intermediate, preparation method therefor and application thereof
CN101379042A (zh) 作为gabaa受体调节剂的取代的噌啉衍生物及其合成方法
HK1224663A1 (zh) 取代的尿嘧啶及其用途
HK1127775A (en) Substituted cinnoline derivatives as gabaa-receptor modulators and method for their synthesis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1120499

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20080903

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1120499

Country of ref document: HK